Vinod Pullarkat, MD
Hematology · Duarte, CANPI 1164433645
Payments from drug & device makers
Across 936 payments — averaging $10,649 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3.5M
- Jazz Pharmaceuticals Inc.$2.5M
- AbbVie$2.2M
- Servier Bioinnovation$1.3M
- Institut DE Recherches Servier$97K
- AstraZeneca$74K
- plus $285K from 28 others
Across 15 payments — averaging $596.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- AbbVie$3K
- Novartis Pharma AG$1K
- Servier Pharmaceuticals LLC$104
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 137 | $3,541,491 |
| Jazz Pharmaceuticals Inc. | 132 | $2,471,486 |
| AbbVie | 277 | $2,164,362 |
| Servier Bioinnovation | 94 | $1,333,153 |
| Institut DE Recherches Servier | 2 | $97,216 |
| AstraZeneca(2 entities) | 63 | $74,236 |
| Sobi, Inc | 20 | $64,719 |
| Sanofi | 11 | $50,315 |
| Amgen | 57 | $44,891 |
| Servier Pharmaceuticals LLC | 36 | $30,604 |
| Dova Pharmaceuticals | 12 | $20,547 |
| Rigel Pharmaceuticals, Inc. | 20 | $17,726 |
| Bristol Myers Squibb | 12 | $11,298 |
| E.r. Squibb & Sons, L.L.C. | 5 | $9,607 |
| Acceleron Pharma, Inc. | 6 | $6,819 |
| Genentech USA, Inc. | 10 | $6,431 |
| Pfizer | 5 | $6,209 |
| Blueprint Medicines Corporation | 4 | $5,780 |
| Pharmacosmos Therapeutics Inc. | 3 | $2,943 |
| Argenx US, Inc. | 1 | $2,800 |
| Agios Pharmaceuticals, Inc. | 1 | $2,800 |
| Gilead | 5 | $488 |
| Syndax Pharmaceuticals, Inc. | 1 | $214 |
| Incyte Corporation | 5 | $192 |
| Beone Medicines USA, Inc. | 2 | $180 |
| Astellas Pharma US Inc | 1 | $154 |
| Seagen Inc. | 2 | $114 |
| Biocryst US Sales Co., LLC | 1 | $103 |
| Daiichi Sankyo Inc. | 4 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Merck | 3 | $61 |
| Johnson & Johnson | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$9,967,185 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Ibrahim AldossDuarte$9.9M
- Haris AliDuarte$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.